Teva moves closer to a drug for celiac disease with positive Phase 2 results

Reports

3

Domains carrying it

3

First reported

2 September 2026

Latest report

3 September 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 2 September 2026Teva moves closer to a drug for celiac disease with positive Phase 2 resultscalcalistech.com
2. 3 September 2026Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trialmedcitynews.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for ...2 reports · 2 domains · 20 August 2026
• Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG ...2 reports · 2 domains · 26 August 2026
• Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier ...2 reports · 2 domains · 1 September 2026

◆ Share

◆ Evidence

3 reports · 3 domains

• Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trialmedcitynews.com · 3 September 2026
• Teva autoimmune antibody notches ph. 2 win in celiac diseasefiercebiotech.com · 2 September 2026
• Teva moves closer to a drug for celiac disease with positive Phase 2 resultscalcalistech.com · 2 September 2026